Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

Published:2017 Issue:3 Volume:2 Page:e000219
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Blackhall Fiona,Ross Camidge D.,Shaw Alice T.,Soria Jean-Charles,Solomon Benjamin J.,Mok Tony,Hirsh Vera,Jänne Pasi A.,Shi Yuankai,Yang Pan-Chyr,De Pas Tommaso,Hida Toyoaki,De Carpeño Javier Castro,Lanzalone Silvana,Polli Anna,Iyer Shrividya,Reisman Arlene,Wilner Keith D.,Kim Dong-Wan

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference12 articles.

1. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007

2. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology;Ou;Oncologist,2012

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis;Cell Death & Disease;2024-08-19

2. Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India;South Asian Journal of Cancer;2024-05-29

3. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature;Diagnostic Pathology;2024-04-14

4. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

5. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-24